| ID | 1042 |
| Name of the vaccine | Infanrix-IPV |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 2 months to 6 years |
| Description of the vaccine | DTaP-IPV vaccine. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | Canada |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Booster vaccine. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium hydroxide |
| Repurposing | For diphtheria, tetanus, pertussis and polio. |
| Side effects of vaccine | Mild pain, redness, swelling, decreased appetite, vomiting, irritability, unusual crying and limb swelling. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=588&keywords= |
| Other name | NA |
| Additional Links | https://www.immune.org.nz/vaccines/available-vaccines/infanrix-ipv
|